Immune-Mediated Therapies for Liver Cancer
AbstractIn recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach for solid tumors. Its premise is based on harnessing the power of the host immune system to destroy tumor cells. Development of immune-mediated therapies, such as vaccines, adoptive transfer of autologous immune cells, and stimulation of host immunity by targeting tumor-evasive mechanisms have advanced cancer immunotherapy. In addition, studies on innate immunity and mechanisms of immune evasion have enhanced our understanding on the immunology of liver cancer. Preclinical and clinical studies with immune-mediated therapies have shown potential benefits in patients with liver cancer. In this review, we summarize current knowledge and recent developments in tumor immunology by focusing on two main primary liver cancers: hepatocellular carcinoma and cholangiocarcinoma. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Aravalli, R.N.; Steer, C.J. Immune-Mediated Therapies for Liver Cancer. Genes 2017, 8, 76.
Aravalli RN, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes. 2017; 8(2):76.Chicago/Turabian Style
Aravalli, Rajagopal N.; Steer, Clifford J. 2017. "Immune-Mediated Therapies for Liver Cancer." Genes 8, no. 2: 76.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.